WO2009084029A2 - Improved process for the preparation of (2r,3s)-2-(2,4- difluqrophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(1h-1,2,4-triazol-1-yl) butan-2-ol - Google Patents

Improved process for the preparation of (2r,3s)-2-(2,4- difluqrophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(1h-1,2,4-triazol-1-yl) butan-2-ol Download PDF

Info

Publication number
WO2009084029A2
WO2009084029A2 PCT/IN2008/000804 IN2008000804W WO2009084029A2 WO 2009084029 A2 WO2009084029 A2 WO 2009084029A2 IN 2008000804 W IN2008000804 W IN 2008000804W WO 2009084029 A2 WO2009084029 A2 WO 2009084029A2
Authority
WO
WIPO (PCT)
Prior art keywords
yl
triazol
butan
ol
2r
Prior art date
Application number
PCT/IN2008/000804
Other languages
French (fr)
Other versions
WO2009084029A3 (en
Inventor
Ami Ramakrishnan
Venkatesh Bhingolikar
Neelam Naidu
Original Assignee
Neuland Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to IN2862/CH/2007 priority Critical
Priority to IN2862CH2007 priority
Application filed by Neuland Laboratories Ltd filed Critical Neuland Laboratories Ltd
Publication of WO2009084029A2 publication Critical patent/WO2009084029A2/en
Publication of WO2009084029A3 publication Critical patent/WO2009084029A3/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Abstract

The present invention is directed to an improved industrially viable, cost effective process to manufacture substantially pure form of (2R,3S)-2-(2,4-difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(1H-1,2,4-triazol-1-yl)butan-2-ol (Voriconazole) with a chiral purity level of greater than 99.9% and impurity level of less than 0.1%.

Description

IMPROVED PROCESS FOR THE PREPARATION OF (2R,3S)-2-(2,4- DIFLUQROPHENYL)-3-(5-FLUOROPYRIMIDIN-4-YL)-l-(lH-l,2,4-TRIAZOL-l-

YL)BUT AN-2-OL

TECHNICAL FIELD OF THE INVENTION

The present invention is directed to an improved industrially viable, cost effective process to manufacture substantially pure form of (2R,3S)-2-(2,4-difluorophenyl)-3-(5- fluoropyrimidin-4-yl)-l-(lH-l,2,4-triazol-l-yl)butan-2-ol (Voricaonazole) with a chiral purity level of greater than 99.9% and impurity level of less than 0.1%.

BACKGROUND OF THE INVENTION

2R,3 S-2-(2,4-difluorophenyl)-3 -(5-fluoropyrimidin-4-yl)- 1 -( 1 H-1 ,2,4-triazol- 1 - yl)butan-2-ol commomly known as Voriconazole of Formula-I,

Figure imgf000002_0001
is a triazole antifungal medication used to treat various fungal infections. These include invasive candidiasis, invasive aspergillosis, and emerging fungal infections.

Voriconazole is commercially available as VFEND® in the form of lyophilized powder for solution in intravenous injection, film-coated tablets for oral administration, and as a powder for oral suspension.

US 5,567,817 and US 5,278,175 discloses a process for the preparation of voriconazole comprising reacting 4-chloro-6-ethyl-5-fluoropyrimidine of Formula IV with 1- (2,4-difluoorophenyl)-2-(lH-l,2,4-triazol-l-yl)ethanone of Formula VI in the presence of lithium diisopropylamine to yield 2-(2,4-difluorophenyl)-3-(4-chloro-5-fluoropyrimidin-4-yl)- l-(lH-l,2,4-triazole-l-yl) butan-2-ol which is further purified by column chromatography to give (2R,3S/2S,3R) enantiomeric pair of 2-(2,4-difluorophenyl)-3-(4-chloro-5- fiuoropyrimidin-6-yl)-l-(lH-l,2,4-triazole-l-yl)butan-2-ol of Formula VII which was dehalogenated with a 10% Pd/C in the presence of sodium acetate, followed by purification using flash chromatography to yield (2R,3S/2S,3R)-2-(2,4-difmorophenyl)-3-(5- fluoropyrimidin-4-yl)-l-(lH-l,2,4-triazole-l-yl)butan-2-ol of Formula VIII and then resolved with R-(-)- 10- camphor sulfonic acid in the presence of methanol and subsequent hydrolysis of the camphor sulfonate salt to free base with alkaline medium to yield Voriconazole of Formula I. The process can be represented as in scheme-I given below,

Scheme I

Figure imgf000003_0001

Dehalogenation R-camphor sulphonic acid 10% Pd/C

Figure imgf000003_0002
Figure imgf000003_0004
Figure imgf000003_0003

The drawbacks of this process are use of hazardous reagents as lithium diisopropylamine for the condensation, the reaction condition are very low temperature of - 780C which is difficult to maintain all the time at manufacturing scale production. The process describes chromatographic separation of the enantiomeric pair which is not advisable at plant scale production and use of palladium carbon for dehalogenation under pressure which is associated with safety problems at plant scale. Moreover the yields are very low.

US 6,586,594 and Organic Process Research & Development (2001), 5(1), 28-36, discloses a process for the preparation of voriconazole comprising reacting 6-(l-bromoethyl)- 2,4-dichloro-5-fluoropyrimidine of Formula IX with l-(2,4-diflouorophenyl)-2-(lH-l,2,4- triazol-l-yl)ethanone of Formula V in the presence of Zinc, lead, iodine and tetrahydrofuran to yield the compound of Formula VII. It also has been disclosed that the compound after the condensation yields two different diastereomeric pairs such as (2R, 3S: 2S, 3R and 2S, 3S; 2R,3R). The desired pair is separated by forming hydrochloride salt. This hydrochloride salt is further dehalogenated with 10%Pd/C to yield compound of Formula VIII, which on resolution with R-(-)-camphor-10-sulphonic acid and further basification to give Voriconazole of Formula I. The process is represented in scheme-II given below

Scheme II

Figure imgf000004_0001

Resolution with camphor sulfonic acid

20% NaHCO,

Figure imgf000004_0002
Figure imgf000004_0003

Voriconazole (2R,3S/2S,3R) Enantiomeric pair I VIIl

The drawbacks of this process are: the formation of HCl salt which requires further basification and thus increases the number of steps and makes the reaction as time consuming process. Moreover use of palladium carbon for dehalogination is not advisable because of the safety problem.

WO2006065726 discloses a process for the preparation of voriconazole comprising reacting 4-chloiO-6-ethyl-5-fluoropyrimidine of Formula V with l-(2,4-diflouorophenyl)-2- (lH-l,2,4-triazol-l-yl)ethanone of Formula VI in the presence of diisopropylamine, n- heptane/THF, n-butyl lithium to yield (2R,3S/2S33R) 2-(2,4-difluorophenyl)-3-(4-chloro-5-

4 fluoropyrimidin-6-yl)-l-(lH-l,2,4-triazole-l-yi) butan-2-ol of Formula VII which is further reduced with Raney Nickel in the presence of sodium acetate to yield (2R,3S/ 2S,3R)-2-(2,4- difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-l-(lH-l,2,4-triazole-l-yl)butan-2-ol of Formula VIII and then resolution with R-(-)-10-camphor sulphonic acid in the presence of methanol to yield camphor sulfonate salt of Formula X followed by hydrolysis of the camphor sulfonate salt to free base with 20% sodium bicarbonate solution in the presence of dichloromethane to give Voriconazole of Formula I. The process is represented in scheme-Ill given below,

Scheme III

Hydrogenation Raney Nickel

Methanol

Figure imgf000005_0001

Figure imgf000005_0002

The drawbacks of this process are: use of hazardous reagents as lithium diisopropylamine for the condensation is not advisable, the reaction condition require low temperature maintainenance i.e. -780C which is difficult to maintain all the time at manufacturing scale, the reaction requires chromatographic separation of the enantiomeric pair which is not advisable at plant scale production, use of Raney nickel for dehalogination under pressure is not advisable because of the safety problem. Moreover the yields are also very low. WO2007013096 discloses the process for the preparation of voriconazole comprising reacting 4-chloro-6-ethyl-5-fluoropyrimidine of Formula V with l-(2,4-diflouorophenyl)-2- (lH-l,2,4-triazol-l-yi)ethanone of Formula VI in the presence of lithium diisopropylamine, n- heptane, tetrahydrofuran to yield (2R,3S/2S,3R) 2-(2,4-difluorophenyl)-3-(4-chloro-5- fluoroρyrimidin-6-yl)-l-(lH-l,2,4-triazole-l-yl) butan-2-ol of Formula VII which is further reduced with Raney Nickel in the presence of sodium acetate to yield (2R,3S/2S,3R)-2-(2,4- difluorophenyl)-3-(5-fluoropyrimidin-4-yl)- 1 -( 1 H- 1 ,2,4-triazole- 1 -yl)butan-2-ol of Formula VIII (racemic Voriconazole) and then resolution with R-(-)-10-camphor sulphonic acid in the presence of methanol to yield camphor sulfonate salt of Formula X followed by hydrolysis of the camphor sulfonate salt to free base with sodium hydroxide solution in the presence of dichloromethane and 2-propanol gives voriconazole of Formula I. The process is represented in scheme-IV given below,

Scheme IV

LDA, n-Heptane Tetrahydrofiiran

Figure imgf000006_0002
Figure imgf000006_0001

Figure imgf000006_0003
Voriconazole

VIII

The drawbacks of this process are use of hazardous reagents as lithium diisopropylamine for the condensation, the reaction has to be maintain at very low temperature of -78°C which is difficult to maintain all the time at manufacturing scale, the reaction requires chromatographic separation of the enantiomeric pair which cannot be done at plant scale, use of Raney nickel for dehalogination under pressure is not advisable because of the safety problem. Moreover the yields are very low.

CN1814597, CN1488629 and CN1488630 discloses the process for the preparation of voriconazole which is as follows: Scheme V

Figure imgf000007_0001
reacting the compound formula II with compound of formula III in an inert organic solvent in the presence of Zn, I2 and a lewis acid, reducing the coupled compounds into I followed by basifying with suitable base to give compound of Formula I.

The drawbacks of this process are use of palladium carbon or Raney nickel for dehalogination is not advisable because of the safety problem. Moreover the yields are very low.

Voriconazole Antifungal. UK-109496.Drugs of the Future (1996), 21(3), 266-271 describes a process a given in scheme below :

Scheme VI

Figure imgf000007_0002

The drawbacks of this process are use of hazardous reagents as lithium diisopropylamine for the condensation, the reaction condition requires low temperature of - 780C which is difficult to maintain at all times at larger scale production and use of Raney nickel for dehalogination under pressure which is not viable at plant scale production, moreover the yields are very low. It's apparent from most of the prior art that; the preparation of voriconazole has certain disadvantages such as

• The^ use of hazardous and costly raw materials like lithium diisopropyl amide, iodine, Pd/C, Raney Ni and n-butyl lithium

• Reaction requires to be maintained at lower temperature which is difficult to maintain all the time at commercial scale

• The processes involves chromatographic purification techniques which is not viable at commercial scale

• More reaction steps and lengthy work-up

• Overall higher cost of production

• Low yields and purity

Therefore, there is a continuing need for developing a new process for the manufacturing of voriconazole which is cost effective, industrially viable and eco-friendly.

SUMMARY OF THE INVENTION

The present invention describes an industrially viable and an improved process for the manufacturing of (2R,3S)-2-(2,4-difluorophenyl)-3-(5-fluoroρyrimidin-4-yl)-l-(lH- l,2,4-triazol-l-yl)butan-2-ol (commonly known as Voriconazole). The process given in Scheme VII which comprises of :

Scheme VII

acid

Figure imgf000008_0001

IX V

Figure imgf000008_0002

Voriconazole

X • reaction of 6-(l-Bromoethyl)-4-chloro-5-fluoro pyrimidine with l-(2,4-difluoro- phenyl)-2-(lH-l,2,4-triazol-l-yl)ethanone in the presence of zinc powder, zinc chloride and THF, followed by dehalogenation in presence of zinc powder and ammonium formate, resolution with suitable resolving agent to give (2R,3S)-2-(2,4- difluoroρhenyl)-3 -(5-fluoropyrimidin-4-yl)- 1 -( 1 H- 1 ,2,4-triazole- 1 -yl)butan-2-ol salt all this in the one pot

• Formation of (2R, 3S)-2-(2, 4-difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-l-(lH-l,2,4- triazole-l-yl)butan-2-ol or Voriconazole by basification.

Another aspect of the present invention provides a process for preparation of racemic Voriconazole which process comprises condensation of 6-(l-Bromoethyl)-4-chloro- 5-fluoro pyrimidine with l-(2,4-difluorophenyl)-2-(lH-l,2,4-triazol-l-yl)ethanone in the presence of zinc powder, zinc chloride and THF followed by dehalogenation in suitable metal catalyst and base to give (2R,3S / 2S,3R)-2-(2,4-difluoroρhenyl)-3-(5-fluoropyrimidin- 4-yl)- 1 -( 1 H- 1 ,2,4-triazol- 1 -yl)butan-2-ol.

Further aspect of the present invention provides a process for preparation of (2R,3 S)-2-(2,4-difluoroρhenyl)-3-(5-fluoroρyrimidin-4-yl)- 1 -(I H- 1 ,2,4-triazole- 1 -yl)butan- 2-ol salt which process comprises reacting racemic (2R,3S / 2$,3R)-2-(2,4-difiuorophenyl)- 3-(5-fluoropyrimidin-4-yl)-l-(lH-l,2,4-triazole-l-yl)butan-2-ol with suitable resolving agent in suitable solvent .

DETAILED DESCRIPTION OF THE INVENTION

The present invention provides an improved process for the preparation of (2R,3S)~ 2-(2,4-difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-l-(lH-l,2,4-triazol-l-yl)butan-2-ol compound of Formula I, which comprises of following steps: a) activation of metal b) condensation of 6-(l-Bromoethyl)-4-chloro-5-fluoro pyrimidine and l-(2,4- difluorophenyl)-2-( 1 H- 1 ,2,4-triazol- 1 -yl)ethanone c) dehalogenation d) resolution e) formation of (2R,3S)-2-(2,4-difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-l-(lH-l,2,4- triazol-l-yl)butan-2-ol by basification Another embodiment of the present invention relates to the single pot synthesis of (2R5 3 S)-2-(2, 4~difluorophenyl)-3-(5-fluoropyrimidin-4-yl)- 1 -( 1 H- 1 ,2,4-triazol-l -yl)butan- 2-ol salt, which process comprises the following steps of a) heating lewis acid and toluene solvent at reflux for 1-1.5 hrs, distilling off toluene, cooling to 600C addition of the THF (co-solvent) followed by the metal, the mixture was again heated to reflux for 3 hrs to complete the activation of the metal, cooling the mixture to -5-00C b) addition of 6-(l-Bromoethyl)-4-chloro-5-fluoro pyrimidine and l-(2,4- diflouorophenyl)-2-(lH-l,2,4-triazol-l-yl)ethanone dissolved in a suitable solvent below 5°C to the activated metal mixture, maintaining the reaction temperature at 0-50C for 30 minutes and distillation of excess solvent to get a thick slurry c) dehalogenation of the compound obtained above by addition of suitable base salt and zinc metal and an organic solvent, stirring the reaction mixture at room temperature for 12-16 hrs, filtering the reacton mixture and quenching with a mixture of water and acetic acid d) basification with saturated sodium carbonate solution followed by neutralization with cone, hydrochloride to form a slurry e) filtration and extraction of the filtrate with ethyl acetate two to three times, combining the ethyl acetate layers, washing with 5% aq. EDTA disodium solution and water, drying over sodium sulphate and distilling off the ethyl acetate layer under reduced pressure at 43-450C to obtain racemic 2-(2,4-difluoroρhenyl)-3-(5-fluoropyrimidin-4- yl)-l -(I H- 1 ,2,4-triazol- 1 -yl)butan-2-ol f) resolving the racemic mixture obtained with suitable resolving agent in presence of organic solvent to get the corresponding salt of (2R,3S)-2-(2,4~difluorophenyl)-3-(5- fluoropyrimidin-4-yl)- 1 -( 1 H- 1 ,2,4-triazol- 1 -yl)butan-2-ol

Another embodiment provides a process for preparation of (2R,3S)-2-(2,4- difluorophenyl)-3 -(5 -fluoropyrimidin-4-yl)- 1 -(I H- 1 ,2,4-triazole- 1 -yl)butan-2-ol salt which process comprises reacting racemic 2-(2,4-difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-l- (lH-l,2,4-triazole-l-yl)butan-2-ol with suitable resolving agent in suitable solvent .

Further embodiment of the present invention give a process for to manufacture (2R,3S/2S,3R)-2-(2,4-difluoroρhenyl)-3-(5-fluoroρyrimidin-4-yl)-l-(lH-l,2,4-triazol-l- yl)butan-2-ol by conversion of the salt to (2R,3S)-2-(2,4-difluoroρhenyl)-3-(5- fluoropyrimidin-4-yl)-l-(lH-l,2,4-triazol-l-yl)butan-2-ol using appropriate base.

10 The metal used in the step (a) can be selected form a group of organometals such as zinc, magnesium, manganese lead metal or mixture thereof

The lewis acid used in step (a) can be selected from zinc chloride or zinc iodide most preferably zinc chloride.

The solvent used for activation and condensation of 6-(l-Bromoethyl)-4-chloro-5- fluoro pyrimidine and l-(2,4-difluorophenyl)-2-(lH-l,2,4-triazol-l-yl)ethanone is selected from a group of solvents consisting of toluene, tetrahydrofuran, diethylether, dimethylether diisopropyl ether, methyl tertiary-butyl ether or 1 ,4-dioxane; most preferably tetrahydrofuran.

The dehalogenation is carried out in the presence of suitable salt and in presence of suitable metal like zinc or magnesium most preferably zinc and suitable base such as ammonium formate, sodium formate, ammonium acetate or sodium acetate most preferably ammonium formate in presence of a suitable organic solvent such as methanol, ethanol or isopropanol most preferably methanol.

The resolving agent used in the step (f) is selected form a group consisting of R-(-)- camphor sulphonic acid, L-(-)-mandelic acid or L-(-)-tartaric acid most preferably R-(-)- camphor sulphonic acid in a suitable solvents selected from a group consisting of ketonic solvents such as acetone, butanone, propanone, ethylmethylketone; alcoholic solvents such as methanol, ethanol, isopropanol or their mixtures and more preferably mixture of ketone: alcohol as acetone: methanol.

The salt is converted in a free base in the presence of suitable base selected from sodium hydroxide, potassium hydroxide, potassium carbonate, sodium carbonate or sodium bicarbonate most preferably sodium hydroxide in a suitable organic solvents selected from a group consisting dichloromethane, chloroform, ethylacetate and more preferably dichloromethane.

The other isomer (2S, 3R)-2-(2,4-difluorophenyl)-3-(5-fluoroρyrimidin-4-yl)-l- (lH-l,2,4-triazol-l-yl)butan-2-ol can be isolated from the mother liquor by the known prior art method.

(2R, 3S)-2-(2,4-difluorophenyl)-3-(5-fluoroρyrimidin-4-yl)-l-(lH-l,2,4-triazol-l- yl)butan-2-ol commonly known as Voriconazole formed by the process disclosed above is crystalline form B.

The examples are provided to illustrate particular aspects of the disclosure and do not limit the scope of the present invention as defined by the claims.

11 ADVANTAGES OF THE PRESENT INVENTION

The advantages of the present invention over the existing processes for the preparation of Voriconazole at a manufacturing scale are :

• Single pot reaction to form desired enantiomer

• Activation of the metal by heating reduces the overall time for the completion of the reaction.

• Use of Zn and ammonium formate in methanol for dehalogenation is cost effective and not hazardous.

• No column purification, which reduces the cost at a manufacturing scale.

• Higher yield and greater chiral purity of the desired compound.

EXAMPLES

Example 1: Preparation of (2R, 3S)-2-(2,4-difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-l- (1 H-1 ,2 ,4-triazol-l-yl)butan-2-ol, R (-)-lO-camphor sulphonate.

Toluene (175 ml) and zinc chloride (39.7 g) were taken together heated to reflux for 1 hr in a Dean-Stark apparatus. Toluene was distilled off completely at atmospheric pressure, mixture cooled to 60°c. Tetrahydrofuran (315 ml) was added to the mixture followed by zinc metal (35 g).The mixture was refluxed for 3 hours, and further cooled to -5°C toO°C. A solution of 6-(l-Bromoethyl)-4-chloro-5-fluoropyrimidine (35gm) and l-(2,4~difiouorophenyi)-2-(lH- l,2,4-triazol-l-yl)ethanone (26gm) in tetrahydrofuran (175ml) was added to this reaction mixture at -5 to 5°C and stirred for 60 minutes. The solvent was distilled off under reduced pressure to get thick slurry. Methanol (175ml), zinc metal (35gm) and ammonium formate (35gm) was added to slurry solution under stirring and maintained for 16 hrs at ambient temperature. The mixture was filtered and then washed with methanol followed by pouring into an aqueous solution of water and acetic acid (350ml: 17ml). The pH was adjusted above 10 using a saturated solution of sodium carbonate solution (~350ml) and further to pH 7.5-8 with cone, hydrochloric acid (60ml).The mixture was then filtered and washed with ethyl acetate (175ml). The filtrate obtained was again extracted with ethyl acetate (2X175ml). The ethyl acetate layer was washed with water (35OmL), 5% aq. EDTA disodium (525ml) and water (35OmL) again, dried over sodium sulphate, filtered and distilled under reduced

12 pressure at 40-450C. The residue is dissolved in acetone (560ml) and to it was added 1-(R)- camphor-10-sulphonic acid (16.6gm) under stirring, the reaction mixture is heated to 500C and refluxed for an hr., cooled to 25-3O0C and stirred at the same temperature for 15 hours, the solid is filtered off washed with acetone and dried at 45-5O0C to get the desired compound. (Dry weight: 13 g).

Example 2: Preparation of (2R, 3S)-2-(2,4-difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-l- (IH-1, 2, 4-triazol-l-yl)butan-2-ol.

To a solution of (2R, 3S)-2-(2,4-difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-l-(lH-l,2,4- triazol-l-yl)butan-2-ol, R (-)-lO-camphor sulphonate (1Og) in dichloromethane(50ml) and water (50ml) was added 40% sodium hydroxide solution(lθml) under stirring. The layers were separated and the aqueous layer was washed with dichloromethane (50ml). The dichloromethane layers were combined, washed with water (2X50ml), dried over sodium sulphate(25gm) and filtered. The solvent was distilled off till one volume of the solvent remained and to it was added isopropyl alcohol(50mL). The distillation is continued under reduced pressure at 40-450C till 3 volumes of isopropanol remained. At this temperature the compound starts isolating. The reaction mixture is cooled to O0C, stirred for one hour, filtered, washed with cold isopropyl alcohol and dried at 45-500C to get the desired compound.. (Dry weight: 5g, CHr al purity: 99.9%, HPLC purity: 99.9 %)

Example 3: Preparation of 2-(2, 4-difluorophenyl)-3-(5~fluoropyrimidin-4-yl)-l-(lH-l, 2, 4- triazol-l-yl)-butan-2-ol

2-(2,4-difluorophenyl)-3-(4-chloro-5-fluoropyrimidin-4-yl)-l-(lH-l,2,4-triazol-l-yl)butan-2- ol hydrochloride (2g) (compound obtained referring to the process as in US 6,586,594) was taken in methanol (20ml) and to it was added ammonium formate (4gm) and stirred for 10 minutes followed by the addition of zinc metal (2gm) and the stirring was continued till reaction completion. The mixture is filtered, washed with methanol and added to an aqueous solution of water and acetic acid (20ml: ImL). The pH is adjusted above 10 with saturated solution of sodium carbonate solution (~20ml) and further to pH about 8 with cone, hydrochloric acid. The mixture is filtered and washed with ethylacetate (5ml). The filtrate is extracted with ethylacetate (3XlOmI). The ethyl acetate layer is washed with water (2OmL), 5% aq. EDTA disodium (30ml) and water (2OmL) again, dried over sodium sulphate, filtered and distilled under reduced pressure at 40-450C, to the residue is added isopropanol (1OmL)

13 and the distillation is continued till the volume is approximately 6mL. The resultant mixture is cooled to 00C, stirred fro 15-20minutes at O0C, filtered, washed with chilled isopropanol and dried to get the desired compound (Dry Weight : 1.2g)

Example 4: Preparation of 2-(2,4-difluorophenyl)-3-(5-fluoropyrimidin-4-yl)~l-(lH-l,2,4- triazol-1 -yl)butan-2-ol.

2-(2,4-difluorophenyl)-3 -(4-chloro-5 -fluoropyrimidin-4-yl)- 1 -( 1 H- 1 ,2,4-triazol- 1 -yl)butan-2- ol hydrochloride (2g) (compound obtained refering to the process as in US 6,586,594)) was taken in methano 1(2OmI) and to it was added ammonium formate (2gm) and stirred for 10 minutes followed by the addition of magnesium metal (2gm) and the stirring was continued till reaction completion. The mixture is filtered, washed with methanol and added to an aqueous solution of water and acetic acid (20ml: ImL). The pH is adjusted above 10 with saturated solution of sodium carbonate solution (~20ml) and further to pH about 8 with cone, hydrochloric acid. The mixture is filtered and washed with ethylacetate (5ml). The filtrate is extracted with ethylacetate (3XlOmI). The ethyl acetate layer is washed with water (2OmL), 5% aq. EDTA disodium (20ml) and water (2mL) again, dried over sodium sulphate, filtered and distilled under reduced pressure at 40-450C, to the residue is added isopropanol (1OmL) and the distillation is continued till the volume is approximately 6mL. The resultant mixture is cooled to, stirred for 15-20 minutes at O0C, filtered, washed with chilled isopropanol and dried to get the desired compound (Dry Weight : 1.2g)

14

Claims

WE CLAIM
1.An improved process for manufacturing (2R, 3S)-2-(2,4-difluoroρhenyl)-3-(5- fluoropyrimidin-4-yl)- 1 -( 1 H- 1 ,2,4-triazol- 1 -yl)butan-2-ol comprising: activation of metal condensation of 6-(l-Bromoethyl)-4-chloro-5-fluoro pyrimidine and l-(2,4- difiouorophenyl)-2-( IH-1 ,2,4-triazol- 1 -yl)ethanone dehalogenation
• resolution
• formation of (2R,3S)-2-(2,4-difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-l-(lH-l,2,4- triazol-l-yl)butan-2-ol by basifi cation
2.One pot synthesis of (2R,3S)-2-(2,4-difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-l-(lH- l,2,4-triazol-l-yl)butan-2-ol, R (-)-lO-camphor sulphonate, comprising: a) heating lewis acid and toluene solvent at reflux for 1-1.5 hrs, distilling off toluene, cooling to 60°C addition of the THF (co-solvent) followed by the metal, the mixture was again heated to reflux for 3 hrs to complete the activation of the metal, cooling the mixture to -5-O0C b) addition of 6-(l-Bromoethyl)-4-chloro-5-fiuoro pyrimidine and l-(2,4- difiouorophenyl)-2-(lH-l,2,4-triazol-l-yl)ethanone dissolved in a suitable solvent below 5°C to the activated metal mixture, maintaining the reaction temperature at 0-50C for 30 minutes and distillation of excess solvent to get a thick slurry c) dehalogenation of the compound obtained above by addition of suitable base salt and zinc metal and an organic solvent, stirring the reaction mixture at room temperature for 12-16 hrs, filtering the reacton mixture and quenching with a mixture of water and acetic acid d) basification with saturated sodium carbonate solution followed by neutralization with cone, hydrochloride to form a slurry e) filtration and extraction of the filtrate with ethyl acetate two to three times, combining the ethyl acetate layers, washing with 5% aq. EDTA disodium solution and water, drying over sodium sulphate and distilling off the ethyl acetate layer under reduced pressure at 43-450C to obtain racemic 2-(2,4-difluorophenyl)-3-(5-fluoropyrimidm-4- yl)- 1 -(1H-1 ,2,4-triazol- 1 -yl)butan-2-ol
15 f) resolving the racemic mixture obtained with suitable resolving agent in presence of organic solvent to get the corresponding salt of . (2R,3S)-2-(2,4-difluorophenyl)-3-(5- fIuoropyrimidin-4-yl)- 1 -( 1 H- 1 ,2,4-triazol- 1 -yl)butan-2-ol
3. One pot synthesis of racemic (2R,3S/2S,3R)-2-(2,4-difluorophenyl)-3-(5-fluoropvrimidin-
4-yl)-l-(lH-l,2,4-triazol-l-yl)butan-2-ol, process which comprises activation of metal followed by condensation with 6-(l-Bromoethyl)-4-chloro-5-fiuoro pyrimidine and 1- (2,4-diflouorophenyl)-2-(lH-l,2,4-triazol-l-yl)ethanone and further dehalogenation to give racemic (2R,3S/2S,3R)-2-(2,4-difluorophenyl)-3-(5-fluoroρyrimidin-4-yl)-l-(lH- 1 ,2,4-triazol- l-yl)butan-2-ol.
4. A process according to claim 1, 2 and 3 wherein the lewis acid is selected from a group like Zinc chloride and Zinc bromide most preferably Zinc chloride and metal catalyst is selected from a group comprising organometal such as zinc, magnesium or manganese most preferably zinc powder.
5. A process according to claim 1, 2 and 3 wherein the solvent used in the activation and condensation as claim 1 and 2 are selected from a group comprising of tetrahydrofuran, diethylether, dimethylether, diisopropyl ether, methyl tertiary-butyl ether and 1 ,4-dioxane more preferably tetrahydrofuran.
6. A process according to claim 1, 2 and 3 wherein the dehalogenation is carried out in the presence of metal like zinc or magnesium most preferably zinc and suitable base such as ammonium formate, sodium formate, ammonium acetate or sodium acetate most preferably ammonium formate in presence of a suitable organic solvent such as methanol, ethanol or isopropanol most preferably methanol.
7. A process for the preparation of (2R,3S)-2-(2,4-difluorophenyl)-3-(5-fiuoropyrimidin-4- yl)-l-(lH-l,2,4-triazol-l-yl)butan-2-ol according to of claim 1 and 2, wherein resolution of the racemic mixture is carried out in the presence of suitable resolving agent selected from R-(-)-camphor sulphonic acid, L-(-)-mandelic acid or L-(-)-tartaric acid most preferably R-(-)-camphor sulphonic acid, in suitable solvents selected from a group comprising of ketonic solvents such as acetone, butanone, propanone, ethylmethylketone; alcoholic solvents such as methanol, ethanol, isopropanol or their mixtures and more preferably mixture of ketone: alcohol as acetone and methanol.
8. ' A process for the preparation of (2R,3S)-2-(2,4-difluorophenyl)-3-(5-fluoropyrimidin-4- yl)-l-(lH-l,2,4-triazol-l-yl)butan-2-ol according to claim 1 and 2 wherein the salt is converted in a free base or (2R,3S)-2-(2,4-difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-l-
16 (lH-l,2,4-triazol-l-yl)butan-2-ol in the presence of suitable organic solvents selected from a group consisting dichloromethane, chloroform, ethylacetate and more preferably dichloromethane.
9. An improved process for the preparation of substantially pure crystalline form of (2R, 3S)-2-(2,4-difluoroρhenyl)-3-(5-fluoroρyrimidin-4-yl)-l-(lH-l,2,4-triazol-l-yl)butan-2- ol (commonly known as Voriconazole) by basification of (2R,3S)-2-(2,4-difluorophenyl)- 3-(5-fluoropyrimidin-4-yl)- 1 -(I H- 1 ,2,4-triazol-l -yl)butan-2-ol salt
10. Substantially pure crystalline form of (2R, 3S)-2-(2, 4-difluorophenyl)-3-(5- fluoropyrimidin-4-yl)-l-(lH-l, 2, 4-triazol-l-yl)butan-2-ol with a chiral purity of greater than 99.9% and impurity level of less than 0.1%.
17
PCT/IN2008/000804 2007-12-03 2008-12-02 Improved process for the preparation of (2r,3s)-2-(2,4- difluqrophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(1h-1,2,4-triazol-1-yl) butan-2-ol WO2009084029A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
IN2862/CH/2007 2007-12-03
IN2862CH2007 2007-12-03

Publications (2)

Publication Number Publication Date
WO2009084029A2 true WO2009084029A2 (en) 2009-07-09
WO2009084029A3 WO2009084029A3 (en) 2010-12-02

Family

ID=40824844

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2008/000804 WO2009084029A2 (en) 2007-12-03 2008-12-02 Improved process for the preparation of (2r,3s)-2-(2,4- difluqrophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(1h-1,2,4-triazol-1-yl) butan-2-ol

Country Status (1)

Country Link
WO (1) WO2009084029A2 (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2173736A2 (en) * 2007-08-06 2010-04-14 Hanmi Pharm. Co., Ltd. Process for preparing voriconazole
KR100971371B1 (en) 2010-02-04 2010-07-20 동국제약 주식회사 Process for preparing voriconazole by using new intermediates
WO2011045807A2 (en) * 2009-10-14 2011-04-21 Neuland Laboratories Ltd. A novel process to manufacture (2r,3s)-2-(2,4-difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(1h-1,2,4-triazol-1-yl)butan-2-ol
WO2011110198A1 (en) 2010-03-10 2011-09-15 Synthron B.V. A process for making voriconazole
KR101435741B1 (en) * 2013-01-17 2014-08-29 (주) 에프엔지리서치 Novel voriconazole intermediate and synthesis of voriconazole
EP3511326A4 (en) * 2016-09-08 2019-08-07 Zhejiang Huahai Pharmaceutical Co., Ltd Method for preparing voriconazole l-camphorsulphonate and voriconazole
US10633368B2 (en) * 2015-12-23 2020-04-28 Zhejiang Huahai Pharmaceutical Co., Ltd. Voriconazole intermediate and voriconazole synthesis method

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997006160A1 (en) * 1995-08-05 1997-02-20 Pfizer Research And Development Company, N.V./S.A. Preparation of triazoles by organometallic addition to ketones and intermediates therefor
WO2007132354A2 (en) * 2006-02-01 2007-11-22 Medichem, S.A. Process for preparing voriconazole, new polymorphic form of intermediate thereof, and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997006160A1 (en) * 1995-08-05 1997-02-20 Pfizer Research And Development Company, N.V./S.A. Preparation of triazoles by organometallic addition to ketones and intermediates therefor
WO2007132354A2 (en) * 2006-02-01 2007-11-22 Medichem, S.A. Process for preparing voriconazole, new polymorphic form of intermediate thereof, and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HUDLICKY: REDUCTIONS IN ORGANIC CHEMISTRY 1984, ELLIS HORWOOD, CHICHESTER, page 68, 181 *

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2173736A4 (en) * 2007-08-06 2011-03-23 Hanmi Holdings Co Ltd Process for preparing voriconazole
US8263769B2 (en) 2007-08-06 2012-09-11 Hanmi Science Process for preparing voriconazole
EP2173736A2 (en) * 2007-08-06 2010-04-14 Hanmi Pharm. Co., Ltd. Process for preparing voriconazole
WO2011045807A2 (en) * 2009-10-14 2011-04-21 Neuland Laboratories Ltd. A novel process to manufacture (2r,3s)-2-(2,4-difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(1h-1,2,4-triazol-1-yl)butan-2-ol
WO2011045807A3 (en) * 2009-10-14 2013-02-07 Neuland Laboratories Ltd. A novel process to manufacture (2r,3s)-2-(2,4-difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(1h-1,2,4-triazol-1-yl)butan-2-ol
WO2011096697A3 (en) * 2010-02-04 2011-12-15 Dongkook Pharmaceutical Co., Ltd. Process for preparing voriconazole by using new intermediates
KR100971371B1 (en) 2010-02-04 2010-07-20 동국제약 주식회사 Process for preparing voriconazole by using new intermediates
JP2013518876A (en) * 2010-02-04 2013-05-23 ドン クック ファーマシューティカル カンパニー リミテッド Method for producing voriconazole using novel intermediate
US8575344B2 (en) 2010-02-04 2013-11-05 Dongkook Pharmaceutical Co., Ltd. Process for preparing voriconazole by using new intermediates
WO2011110198A1 (en) 2010-03-10 2011-09-15 Synthron B.V. A process for making voriconazole
KR101435741B1 (en) * 2013-01-17 2014-08-29 (주) 에프엔지리서치 Novel voriconazole intermediate and synthesis of voriconazole
US10633368B2 (en) * 2015-12-23 2020-04-28 Zhejiang Huahai Pharmaceutical Co., Ltd. Voriconazole intermediate and voriconazole synthesis method
EP3511326A4 (en) * 2016-09-08 2019-08-07 Zhejiang Huahai Pharmaceutical Co., Ltd Method for preparing voriconazole l-camphorsulphonate and voriconazole

Also Published As

Publication number Publication date
WO2009084029A3 (en) 2010-12-02

Similar Documents

Publication Publication Date Title
US8871942B2 (en) Process for producing 1-triazole-2-butanol derivatives
KR930011039B1 (en) Triazole antifungal agents
JP5269798B2 (en) Trityl olmesartan medoxomil and method for producing olmesartan medoxomil
US7560575B2 (en) Process for preparation of racemic Nebivolol
EP1912952B1 (en) Process for preparing amorphous rosuvastatin calcium free of impurities
AU703337B2 (en) Preparation of triazoles by organometallic addition to ketones and intermediates therefor
RU2561732C2 (en) Methods for synthesis of dihydropyridophthalazinone derivatives
EP1881954B1 (en) Process for preparing cinacalcet hydrochloride
EP3044212B1 (en) Process for the large scale production of 1h- [1,2,3]triazole and its intermediate 1-benzyl-1h-[1,2,3]triazole
RU2434009C1 (en) Method of producing voriconazole
US8188285B2 (en) Purification process of Montelukast and its amine salts
US9073904B2 (en) Preparation of posaconazole intermediates
ES2369746T3 (en) Method for the preparation of medetomidine and its salts.
TWI453198B (en) Process for making the trans-1-( (1r , 3s)- 6-chloro - 3 -phenylindan-1- yl ) - 3 , 3 - dimethylpiperazine and salts thereof and for making 4 -((1r , 3s )-6- chloro- 3- phenylindan -1- yl )-1, 2 , 2 -trimethylpiperazine and salts thereof
JP2004518675A5 (en)
US7655806B2 (en) Process for purification of anastrozole
US5294722A (en) Process for the preparation of imidazoles useful in angiotensin II antagonism
US9216943B2 (en) Preparation of fingolimod and its salts
EP2632889B1 (en) Intermediate compounds and process for the preparation of fingolimod
US20100249430A1 (en) Process for preparing valsartan
EP2968375A1 (en) Methods for preparing sglt2 inhibitors
JP2004520446A (en) Crystallization method of losartan potassium
DE102005037484A1 (en) Preparation of pure anastrozole useful to treat e.g. breast cancer involves dissolving 3,5-bis(2-cyanoprop-2-yl)benzylbromide in organic solvent other than carbon tetrachloride, then reacting with sodium thiazole or triazole, and purifying
WO2008010022A2 (en) A process for preparation of racemic nebivolol
US6710183B2 (en) Process for the synthesis of a known tetrazol derivative

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08867864

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08867864

Country of ref document: EP

Kind code of ref document: A2